Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Mereo BioPharma Group plcNASDAQ: MREO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $1.61M fell 29.5% year over year, behind the -9.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 4.0% from the prior quarter. Over 3 fiscal years it compounded at +16.8% a year.

Context

  • Stock-based compensation amounted to 1519.6% of revenue in FY2025.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -29.5% toward the trailing-twelve-month pace of -9.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.61M+4.0% QoQ
Last fiscal yearDec 2025
$7.6M+2.8% YoY
LTMMar 2026
$6.93M-9.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.5%——
1 year+2.8%——
3-year CAGR+16.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
7.6M USD
Year-over-year change
+2.8%
4-year CAGR
+14.3%

Stock-Based Compensation vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.1% is the 5th highest of 10, against a peer median of -19.1%.
  • Stock-based compensation amounts to 1385.0% of revenue for MREO, versus a peer median of 49.0%.
MREO Competitors
Stock-Based Compensation for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$3.98B USD+32410.1%+56.9%—
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$11.29M USD+31.2%+73.3%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$11.19M USD-19.1%+89.6%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$11.09M USD+34.6%+121.4%—
MREOMereo BioPharma Group plcLTM Mar 2026$6.93M USD-9.1%+16.8%1385.0%
CADLCandel Therapeutics, Inc.LTM Mar 2026$4.96M USD+8.1%+18.3%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$2.88M USD-66.7%-9.8%—
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.03M EUR-21.0%—15.1%
IMMPImmutep LimitedFY2025A$1.16M AUD-35.2%-7.8%23.1%
Peer median (excluding MREO) —-19.1%+37.6%49.0%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income19.22M(42.22M)(29.47M)(43.25M)(41.88M)
Depreciation & Amortization866.47K889K1.06M1.09M622K
Deferred Income Tax00000
Stock-Based Compensation4.46M4.77M4.92M7.39M7.6M
Change in Working Capital(2.49M)(2.35M)(1.59M)(369K)(3.21M)
Accounts Receivables(794.94K)(3.47M)456K(1.65M)1.4M
Inventory00000
Accounts Payables0617K(1.26M)146K(1.38M)
Other Working Capital(1.7M)498K(786K)1.13M(3.23M)
Other Non-Cash Items(29.12M)(9.91M)3.94M2.31M5.9M
Operating Cash Flow(7.07M)(48.82M)(21.13M)(32.83M)(30.97M)
Capital Expenditures(722.06K)(13K)(419K)(699K)(20K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities153.86K2M(419K)00
Investing Cash Flow(568.2K)1.99M(419K)(699K)(20K)
Debt Repayment(933.95K)0(3.19M)00
Common Stock Issued105.99M011.61M47M327.76K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(253.73K)200K24K(853K)(764)
Financing Cash Flow104.8M200K7.97M46.15M327K
Effect of Forex Changes(1.57M)(12.58M)2.82M(233K)1.93M
Net Change in Cash95.59M(59.22M)(10.76M)12.38M(28.81M)
Free Cash Flow(7.79M)(48.83M)(21.55M)(33.53M)(30.99M)

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.